MX9304547A - Derivados 1-piperazinil-n-fenilacetamida de 4,5-difenil-oxazoles, tiazoles e imidazoles, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen. - Google Patents

Derivados 1-piperazinil-n-fenilacetamida de 4,5-difenil-oxazoles, tiazoles e imidazoles, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen.

Info

Publication number
MX9304547A
MX9304547A MX9304547A MX9304547A MX9304547A MX 9304547 A MX9304547 A MX 9304547A MX 9304547 A MX9304547 A MX 9304547A MX 9304547 A MX9304547 A MX 9304547A MX 9304547 A MX9304547 A MX 9304547A
Authority
MX
Mexico
Prior art keywords
oxazoles
thiazoles
imidazoles
piperazinyl
diphenyl
Prior art date
Application number
MX9304547A
Other languages
English (en)
Inventor
Neelakantan Balasubramanian
Original Assignee
Bristol Meyers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Meyers Squibb Co filed Critical Bristol Meyers Squibb Co
Publication of MX9304547A publication Critical patent/MX9304547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe una serie de derivados de 1-piperazinil-N-fenilacetamida de 4,5-difenil-oxazoles, tiazoles e imidazoles, los cuales son nuevos inhibidores del transporte de la adenosina, y los cuales se ha encontrado que proporcionan protección antiisquémica efectiva para el tejido del sistema nervioso central, particularmente las neuronas. Se describe un método de tratamiento para proteger contra la isquemia del sistema nervioso central, tal como aquella que resulta de trauma, apoplejía, u otras condiciones isquémicas, que comprende la administración de estos nuevos compuestos a un individuo en necesidad de tal tratamiento.
MX9304547A 1992-07-31 1993-07-28 Derivados 1-piperazinil-n-fenilacetamida de 4,5-difenil-oxazoles, tiazoles e imidazoles, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen. MX9304547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92339992A 1992-07-31 1992-07-31
US4833893A 1993-04-15 1993-04-15

Publications (1)

Publication Number Publication Date
MX9304547A true MX9304547A (es) 1994-02-28

Family

ID=26726027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304547A MX9304547A (es) 1992-07-31 1993-07-28 Derivados 1-piperazinil-n-fenilacetamida de 4,5-difenil-oxazoles, tiazoles e imidazoles, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen.

Country Status (20)

Country Link
US (1) US5382584A (es)
EP (1) EP0582164B1 (es)
JP (1) JP3478852B2 (es)
KR (1) KR940005614A (es)
CN (1) CN1085216A (es)
AT (1) ATE174913T1 (es)
AU (1) AU670953B2 (es)
CA (1) CA2101311A1 (es)
DE (1) DE69322707T2 (es)
DK (1) DK0582164T3 (es)
ES (1) ES2125285T3 (es)
FI (1) FI933398A (es)
GR (1) GR3029778T3 (es)
HK (1) HK1014714A1 (es)
HU (1) HUT67460A (es)
IL (1) IL106490A0 (es)
MX (1) MX9304547A (es)
NO (1) NO932694L (es)
PL (1) PL299888A1 (es)
TW (1) TW224096B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712392A (en) 1990-12-28 1998-01-27 Neurogen Corporation Certain 4-piperidine- and piperazinoalkyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
AU4174096A (en) * 1994-11-23 1996-06-17 Glaxo Wellcome Inc. Oxazole derivatives as antagonists of alpha-1c adrenergic receptors
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
AU6167696A (en) * 1995-06-07 1996-12-30 Dade Chemistry Systems Inc. Preparation of immunogens and other conjugates of drugs
AU707347B2 (en) * 1996-04-03 1999-07-08 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5866574A (en) * 1997-04-10 1999-02-02 Kyowa Hakko Kogyo Co., Ltd. Pancreatitis remedy
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6462034B1 (en) 1998-04-03 2002-10-08 Theravance, Inc. Local anesthetic compounds and uses
PE20000354A1 (es) 1998-04-03 2000-05-20 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
US7582680B1 (en) * 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
DE19924819A1 (de) * 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäurebenzylamid (Adenosinaufnahmeinhibitoren)
DE19924818A1 (de) * 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide
US6570016B1 (en) * 1999-06-03 2003-05-27 Eli Lilly And Company Process for preparing a 10,11-methanodibenzosuberane derivative
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
DE10044792A1 (de) * 2000-09-11 2002-04-04 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide und ihre Verwendung
AR030817A1 (es) 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona
JPWO2002076962A1 (ja) * 2001-03-23 2004-07-15 日本曹達株式会社 ３−オキソ−２−（２−チアゾリル）プロパンニトリルの製造方法および中間体
ATE546146T1 (de) * 2001-04-24 2012-03-15 Purdue Research Foundation Verfahren und zusammensetzungen zur behandlung von nervengewebeverletzungen in säugetieren
US6649761B2 (en) * 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
DE10150310A1 (de) * 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
JP4846234B2 (ja) 2002-06-24 2011-12-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｎ−（２，６−ジメチル−フェニル）−２−ピペラジン−１−イル−アセトアミドの製造方法
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
WO2011000945A2 (en) 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
KR101423176B1 (ko) 2011-11-29 2014-07-25 제일모직 주식회사 포지티브형 감광성 수지 조성물, 이를 사용하여 제조된 감광성 수지막 및 상기 감광성 수지막을 포함하는 반도체 소자
KR101432603B1 (ko) 2011-12-29 2014-08-21 제일모직주식회사 감광성 노볼락 수지, 이를 포함하는 포지티브형 감광성 수지 조성물, 이를 사용하여 제조된 감광성 수지막 및 이를 포함하는 반도체 소자
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
EA201790806A1 (ru) 2014-11-05 2017-11-30 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
CN109456285A (zh) * 2018-10-29 2019-03-12 安徽省庆云医药股份有限公司 一种雷诺嗪的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137318C (es) * 1964-06-09
IT1033040B (it) * 1970-02-21 1979-07-10 Serono Ist Farm 4 5 difenilossazoli 2 amminometil e 2,2 amminoetil sostituiti
US4020082A (en) * 1970-02-21 1977-04-26 Enzo Marchetti 2-Aminomethyl- and 2-(2-aminoethyl)-substituted 4,5-diphenyloxazoles
US4101660A (en) * 1976-02-12 1978-07-18 Mitsubishi Chemical Industries Limited 2-Aminomethyl-5-phenyloxazoles and the pharmaceutically acceptable acid addition salts thereof
FR2459242A1 (fr) * 1979-06-21 1981-01-09 Delalande Sa Derives du benzimidazole portant en position 1 une chaine aralkyle substituee, leur procede de preparation et leur application en therapeutique
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions
JP2852659B2 (ja) * 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
JP3003148B2 (ja) * 1989-01-05 2000-01-24 藤沢薬品工業株式会社 チアゾール化合物、その製造法およびそれを含有する医薬組成物
CA2012716A1 (en) * 1989-03-22 1990-09-22 Akito Tanaka Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
WO1991004032A1 (en) * 1989-09-15 1991-04-04 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
DK0618905T3 (da) * 1991-12-18 1995-12-04 Schering Corp Imidazolyl-alkyl-piperazin- og -diazepinderivater som histamin H3-agonister/antagonister

Also Published As

Publication number Publication date
PL299888A1 (en) 1994-04-18
NO932694L (no) 1994-02-01
FI933398A0 (fi) 1993-07-29
CN1085216A (zh) 1994-04-13
JP3478852B2 (ja) 2003-12-15
ATE174913T1 (de) 1999-01-15
JPH06157472A (ja) 1994-06-03
AU670953B2 (en) 1996-08-08
KR940005614A (ko) 1994-03-21
EP0582164A1 (en) 1994-02-09
EP0582164B1 (en) 1998-12-23
US5382584A (en) 1995-01-17
GR3029778T3 (en) 1999-06-30
DE69322707D1 (de) 1999-02-04
FI933398A (fi) 1994-02-01
IL106490A0 (en) 1993-11-15
HK1014714A1 (en) 1999-09-30
CA2101311A1 (en) 1994-02-01
TW224096B (es) 1994-05-21
HUT67460A (en) 1995-04-28
AU4423293A (en) 1994-02-03
DE69322707T2 (de) 1999-08-19
ES2125285T3 (es) 1999-03-01
DK0582164T3 (da) 1999-08-23
NO932694D0 (no) 1993-07-27

Similar Documents

Publication Publication Date Title
MX9304547A (es) Derivados 1-piperazinil-n-fenilacetamida de 4,5-difenil-oxazoles, tiazoles e imidazoles, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
BR9206632A (pt) Sistema de penetração na pele melhorado para melhorada liberação tópica de drogas
AR009357A1 (es) Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa
RU95104885A (ru) 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция
ES2116131T3 (es) Derivados de naftaleno, su procedimiento de preparacion y productos intermediarios adecuados, y las composiciones farmaceuticas que los contienen.
RU94046306A (ru) Производные индолокарбазолимида, смесь их изомеров или отдельные изомеры и их соли и фармацевтическая композиция с активностью, ингибирующей протеинкиназу с или киназу легкой миозиновой цепи или подавляющей иммунные реакции
MX9304359A (es) Derivados de rapamicina.
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
CO4920242A1 (es) Compuestos inhibidores de metalopreoteasas 1,4-heterocicli- cos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
GT198900008A (es) Derivados de quinolina, quinazolina y cinolina.
MX9203438A (es) Metodo para inhibir el crecimiento de celulas progenitoras.
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
RU94041836A (ru) Производные амидина, смесь их изомеров или отдельные изомеры и их соли, фармацевтическая композиция с антагонистической в отношении лейкотриена в*004 активностью
MX9304361A (es) Derivados de rapamicina.
RU94002337A (ru) Фармацевтическая композиция, применение гамма-линоленовой или дигомо-гамма-линоленовой кислоты для лечения поражений после облучения, способ лечения
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
ES2148268T3 (es) Composicion farmaceutica para prevenir o tratar fracturas de huesos.
ES2164454T3 (es) Nuevos compuestos derivados de acido alquilendiamina di o tri-acetico, su procedimiento de preparacion, su utilizacion en composiciones cosmeticas y farmaceuticas y composiciones que los contienen.
ES2132503T3 (es) Derivado de diarilheptanoide y composicion farmaceutica que lo contiene.
ES2144844T3 (es) Derivados ureido biologicamente activos utiles en el tratamiento de la esclerosis en placas.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.